Profound Medical Corp (PRN) Fair Value & Analysis
Healthcare · CA · Market cap C$339M
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price −1.4% over the past month.
Price vs Fair Value (12 months)
12‑month range C$5.33 – C$12.07 · fair‑value band C$6.16 – C$10.27 · the C$9.37 price screens above the C$8.21 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Profound Medical Corp (PRN) currently trades at C$9.37, while our model-based Fair Value estimate is C$8.21 — implying the stock looks roughly 12.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at C$18.8M. Revenue grew 103.6% year over year. It earns a return on equity of -70.6%. The balance sheet holds a net cash position of C$54.9M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Profound Medical Corp reported revenue of C$16.4M in FY2025 versus C$6.9M in FY2021, a compound +24.2%/yr. Reported net income was −C$43.3M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 82.40 MXN | -95% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Profound Medical Corp (PRN) undervalued?
What is the fair value of PRN?
What is the quality score of PRN?
What is the revenue of Profound Medical Corp (PRN)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.